Apoptosis induction in acute promyelocytic leukemia cells through upregulation of CEBPα by miR-182 blockage

MicroRNAs (miRNAs) involved in regulation of the genes. The CCAAT/enhancer-binding protein-α (CEBPα) is a crucial transcription factor for normal hematopoiesis and cell cycle that frequently disrupted in human acute myeloid leukemia (AML). The miR-182 up-regulation in several malignant diseases such as AML was reported, in the other hand bioinformatics analysis revealed CEBPα targeted by miR-182.miR-182-5p inhibition in human acute promyelocytic leukemia (APL) cell line was performed by using locked nucleic acid (LNA) and subsequently miR-182-5p and CEBPα expression, apoptosis, necrosis and cell proliferation were measured. After LNA-anti-miR-182-5p transfection to cells at different time points, miR-182-5p down regulation and CEBPα overexpression was revealed in the LNA-anti-miR group compared to the control groups. The cell viability was meaningfully varied between LNA-anti-miR and control groups. Increasing of the apoptotic ratio was linked to miR-182-5p inhibition in the LNA-anti-miR group rather than other groups. Similarly, the necrotic ratio in the LNA-anti-miR group was higher.Our results supported the hypothesis that miR-182-5p inhibition can reduce the cell viability predominantly due to induces apoptosis and necrosis. The present results can apply in translational medicine for investigation of antisense therapy and drug development in leukemia.


INTRODUCTION
Acute promyelocytic leukemia (APL) is one of the severe forms of acute leukemia with a very fast clinical signs start, poor response to chemotherapy treatment and disseminated intravascular coagulation that is characterized by high mortality rates [1]. This leukemia mainly causes due to translocation between retinoic acid receptor alpha (RARα) gene and acid promyelocytic leukemia (PML) gene [2][3][4]. Hematopoiesis is an extremely arranged interaction of lineage-specific transcription factors that moving pluripotent precursor cells to the differentiated mature blood cells [5]. The evidences suggests that this differentiation besides the various hematopoietic lineages is somewhat regulated by microRNAs (miRNAs) [6]. Thus, expression of definite transcription factors was regulated by miRNAs in post-transcriptional level [7]. Hematopoietic transcription factors or miRNAs deregulation is a common episode in the molecular pathogenesis process of human leukemias [8]. The CCAAT/enhancer-binding protein-α (CEBPα) is a crucial transcription factor for normal hematopoiesis that frequently disrupted in human acute myeloid leukemia (AML). The CEBPα gene has a vital role for myeloid differentiation towards mature granulocytes [9]. The various CEBPα downstream effectors during the normal hematopoiesis including miR-223 have been defined [10]. The potentially anti-proliferative effect of CEBPα in myeloid cells recommended that it maybe function as a suppressor for leukemogenesis [11]. Pabst et al, represented that 7.3% of AML patients carried spontaneous CEBPα mutations in the tumor cell DNA [12].
MiRNAs are short non-coding RNA, about 19-25 nucleotides and play an important role in biological processes such as cell cycle, differentiation, growth, metabolism, aging and apoptosis. MiRNAs plays a key role in a wide range of diseases including cardiovascular diseases, rheumatologic, infectious, inflammatory, autoimmune, metabolic and cancer [13]. Up to now, the role of miRNAs in a number of cancers has been shown, for example, overexpression of miR-21 in breast cancer and miR-145 downregulation in lung cancer was reported. The miR-183/96/182 cluster is a highly conserved miRNA cluster that their members are located on 7q32.2 human chromosome that is abnormally expressed in a variety of tumors [14]. MiR-182 belongs to the miR-183-96-182 cluster that plays a vital role in tumorgenesis and cancer development [14]. Among these miRNAs cluster, miR-182 is an oncogene and their oncogenic features confirmed by negative regulation of multiple tumor suppressor genes including HMGA2, BRCA1, FOXO3, and MTSS1 [15][16][17][18]. The overexpression of miR-182 in breast cancer, melanoma, lung, colon and prostate cancer have been reported [19,20]. Upregulation of miR-182 in Chronic lymphocytic leukemia (CLL) [21] and in APL was described [22]. In the present study using the bioinformatics softwares include miRanda, miRDB, miRWalk and Targetscan predicted that CEBPα targeted by miR-182. Also, previous described the CEBPα gene is a one of a target gene of miR-182 [23].
According to these evidences, we suggested inhibition of miR-182-5p has been antiproliferation effect on APL through regulation of CEBPα gene. In the present study, miR-182-5p inhibition was done by LNA to assess their effect on cell proliferation and apoptosis through regulation of CEBPα gene in APL cell line (HL-60).

MATERIALS AND METHODS
This study was approved by the local ethics committee of Isfahan University of Medical Sciences (IRAN) and the studies have been approved by the appropriate institutional and/or a national research ethics committee and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Reverse transcriptase microRNA real-time PCR: To determination efficiency of miR-182-5p inhibition by LNA-anti-miR, qRT-PCR were done. In the 24, 48 and 72 h after transfection, total RNA extracted by miRCURY RNA Isolation Kit (Exiqon, Copenhagen, Denmark), and then cDNA synthesized by Universal cDNA Synthesis Kit (Exiqon, Copenhagen, Denmark). The qPCR by SYBR Green Master Mix Kit was done (Exiqon, Copenhagen, Denmark) and specific primers for miR-182-5p obtained from Exiqon. For qPCR tests was used ABI Step One Plus (Applied Biosystems, Foster City, CA, USA) instrument and ΔΔCt method for data analysis.

Data analysis:
All experiments were repeated three times. The results were analysis by SPSS version 20 (IBM, New York, NY, USA) software. Two-way ANOVA (two-way analysis of variance) also post hoc test to examine were considered. Data presented as mean ± SD. Statistical significance was defined as p<0.05.

RESULTS
Since the oligonucleotides have been fluorescence-conjugated, transfection efficiency determined by fluorescence microscopy. Transfection efficiency was approximately 90% (Fig.  1). The miR-182-5p expression was considered by qRT-PCR in transfected group with LNAanti-miR, scrambled and untreated groups at three-time points 24, 48 and 72 h after transfection.
The expression of miR-182-5p was noticeably lower in the LNA-anti-miR group compared with the control groups (P<0.025). MiR-182-5p expression at 24 h after transfection was at the lowest level and steadily increased at the next time points (Fig. 2).  Expression level of CEBPα gene was considered in HL-60 cells include LNA-anti-miR group, scrambled and untreated groups by qRT-PCR at three-time points 24, 48, and 72 h after transfection. In the LNA-anti-miR group the CEBPα expression after transfection was increased rather than untreated groups (p<0.021). The upper-level expression of CEBPα was at 72 h after transfection in HL-60 cells (Fig. 3). The MTT assay results revealed cell viability meaningfully decreased in HL-60 cells after LNA-anti-miR transfection. The cell viability in LNA-anti-miR group of HL-60 cells steadily increased over time. The difference in cell viability was statistically significant between LNAanti-miR group compared with scrambled and untreated groups (P>0.024) in 24, 48 and 72 h after transfection (Fig. 4). Apoptosis dramatically increased in HL-60 cells transfected by LNA-anti-miR and miR-182-5p inhibition linked with apoptosis as higher than in the LNA-anti-miR group compared to another groups at three-time points ( Figure 5, 6 a; P< 0.028). Also, necrosis significantly increased in HL-60 cells transfected by LNA-anti-miR compared to another groups at three-time points ( Figure 5, 6 b; P< 0.03).

DISCUSSION
The family transcription factors of CCAAT/enhancer-binding protein (CEBP) shows an important role in cell proliferation and differentiation. The CEBPα has a predominantly regulatory effect on cell-cycle exit and induced in terminally differentiating myeloid and adipocytes cells and also activates differentiation-specific genes. The growth-inhibiting action of CEBPα suppresses the tumorigenesis processing in myeloid cells and probably other tissues. Also, CEBPα act as a member of p53-regulated growth arrest response that produced by DNA damage [11]. The expression forced of CEBPα obligates 3T3-L1 pre-adipoblasts to adipocyte differentiation and induces cell-cycle arrest [26], and also the antiproliferation activity of CEBPα encompasses to hepatocytes and Saos2 osteosarcoma cells have been described [27].
The role of miRNAs in cancers and especially deregulation of miRNAs in human leukemias has been described [28], for example up-regulation of miR-182 in Chronic lymphocytic leukemia (CLL) [21] and in APL was described [22]. Overexpression of miR-92a targeting FBXW7 in cervical cancer cells and increased proliferation and tumorgenesis [29]. miR-503 and miR-182 in colon cancer cells were overexpressed and increased proliferation [30]. FOXO1 is a target of miR-182 that is a transcription factor for regulating genes involved in apoptosis, cell cycle and metabolism. Decreased expression of this transcription factor by overexpression of miR-182 in the breast cancer causes a disturbance in apoptosis [31]. Up-regulation of the miR-183/96/182 cluster is associated with metastatic features in hepatocellular carcinoma [32]. Up to now, several miRNAs reported as pro-metastatic such as miR-10b, miR-373, miR-520c, miR-21, miR-143 and miR-182 [33]. Up-regulation of miR-189, miR-21 and also downregulation of let-7 family in breast cancer were described [34].
In this study we used LNA-anti-miR for silencing of miR-182 in APL cell line. Nearly complete miR-182-5p downregulation was confirmed after LNA-anti-miR transfection by qRT-PCR. The decrease of cell viability revealed associated with miR-182-5p blockage through regulation of CEBPα by MTT assay. Our data confirmed by apoptosis and necrosis assay due to increased apoptosis and necrosis after LNA-anti-miR-182 transfection. The present study results suggested miR-182-5p inhibition can reduction the cell viability predominantly due to induces apoptosis and necrosis through regulation of CEBPα gene in APL cell line.
As mention above due to oncogenic role of miR-182-5p and their effect on CEBPα as potentially anti-proliferative in myeloid cells, therapeutic strategies using inhibition of miR-182 in APL and other malignant disorders may be useful. The previous studies represented therapeutic strategies by miRNA inhibitors as cancer treatment [35][36][37]. The LNA is one of the technology as anti-miRNA that used for oncogenic miRNAs inhibition [38]. MiRNAs therapy now reaches the clinical trial stage and promising in cancer treatment. All-Trans Retinoic Acid (ATRA) used for the treatment of APL but a subset of APL patients is not cured with ATRA [39], in this cases maybe combination therapy with LNA-anti-miR and ATRA can cure effect although in vivo studies in the future need to evaluate the feasibility of this strategy.